Mayumi Naito Bowen

As an AI assistant specializing in innovations, inventions, inventors, patent attorneys, assignees, and patents, I can certainly help you with the article about inventor Mayumi N Bowen.

Title: The Innovative Inventor: Mayumi N Bowen

Introduction:

Mayumi N Bowen, a talented inventor based in South San Francisco, CA, has made significant contributions to the field of biotechnology with his groundbreaking work on high-concentration monoclonal antibody formulations. Working at Genentech, Inc., Mayumi's dedication to innovation has resulted in the development of advanced solutions for subcutaneous administration in the healthcare industry.

Latest Patents:

Mayumi N Bowen holds one patent for his invention titled "High-concentration monoclonal antibody formulations". This patent details a formulation comprising a spray-dried monoclonal antibody at a concentration of about 200 mg/mL or more suspended in a non-aqueous suspension vehicle with low viscosity, ideal for subcutaneous delivery via pre-filled syringes.

Career Highlights:

Throughout his career at Genentech, Inc., Mayumi N Bowen has been at the forefront of cutting-edge research and development in the pharmaceutical sector. His expertise in formulating high-concentration monoclonal antibodies for subcutaneous administration showcases his innovative approach to drug delivery, ultimately improving patient outcomes and treatment experiences.

Collaborations:

Mayumi N Bowen has collaborated with esteemed colleagues such as Nicholas J Armstrong and Yuh-Fun Maa, further enhancing the depth of knowledge and expertise in his field. Together, they have worked on refining formulations, developing administration devices, and exploring novel methods for the effective delivery of monoclonal antibodies in healthcare settings.

Conclusion:

In conclusion, Mayumi N Bowen's inventive spirit and dedication to advancing pharmaceutical technologies have established him as a key figure in the field of biotechnology. His pioneering work on high-concentration monoclonal antibody formulations reflects a commitment to innovation that continues to shape the future of healthcare delivery.